Cambium Bio
Clinical-stage regenerative medicine company developing biologic therapies for ophthalmology and tissue regeneration. Uses human platelet lysate and mesenchymal stem cell-based platforms to advance a pipeline that includes a topical platelet-derived ophthalmic candidate for dry eye disease and cell/secretome programs for osteoarthritis and wound healing. Publicly listed with active clinical and regulatory programs.
Industries
Nr. of Employees
small (1-50)
Products
Elate Ocular
Topical ophthalmic biologic derived from human platelet material being developed to treat dry eye disease; advanced to late clinical stages with regulatory interactions for Phase 3.
Progenza
Therapeutic program based on mesenchymal stem cells and secretome intended for intra-articular use in knee osteoarthritis; previously studied in early clinical trials.
Sygenus
Secretome-based therapeutic program in preclinical development for wound healing indications.
Aurarix®
Proprietary, enriched, fibrinogen-depleted, allogeneic human platelet lysate platform technology used as a supplement in cell culture processes and across various therapeutic markets.
Elate Ocular
Topical ophthalmic biologic derived from human platelet material being developed to treat dry eye disease; advanced to late clinical stages with regulatory interactions for Phase 3.
Progenza
Therapeutic program based on mesenchymal stem cells and secretome intended for intra-articular use in knee osteoarthritis; previously studied in early clinical trials.
Sygenus
Secretome-based therapeutic program in preclinical development for wound healing indications.
Aurarix®
Proprietary, enriched, fibrinogen-depleted, allogeneic human platelet lysate platform technology used as a supplement in cell culture processes and across various therapeutic markets.
Expertise Areas
- Regenerative medicine
- Ophthalmology therapeutics
- Cell therapy development
- Clinical trial management
Key Technologies
- Human platelet lysate (HPL)
- Mesenchymal stem cell (MSC) therapies
- Cell secretome-based therapeutics
- Potency and bioassay development
News & Updates
Regulatory approval of Phase 3 clinical trial protocol for the lead ophthalmic program.
Regulatory acceptance of the potency assay strategy to support Phase 3 clinical trials.
Regulatory clearance supporting commencement of Phase 3 dosing for the ophthalmic program.
Fast Track designation granted for the company's lead ophthalmic program.
Multiple placements and financing rounds reported via ASX announcements to support corporate activities and development programs.
Article reporting market reaction to the merger transaction that enabled market entry.
Regulatory approval of Phase 3 clinical trial protocol for the lead ophthalmic program.
Regulatory acceptance of the potency assay strategy to support Phase 3 clinical trials.
Regulatory clearance supporting commencement of Phase 3 dosing for the ophthalmic program.
Fast Track designation granted for the company's lead ophthalmic program.
Multiple placements and financing rounds reported via ASX announcements to support corporate activities and development programs.
Article reporting market reaction to the merger transaction that enabled market entry.